Krystal Biotech. has filed a patent for a pharmaceutical composition containing a virus with transgenes encoding specific polypeptides to enhance skin proteins. The composition aims to provide relief for skin disorders like epidermolysis bullosa. GlobalData’s report on Krystal Biotech gives a 360-degree view of the company including its patenting strategy. Buy the report here.

Smarter leaders trust GlobalData


Data Insights Krystal Biotech Inc - Company Profile

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

According to GlobalData’s company profile on Krystal Biotech, Oncolytic viruses was a key innovation area identified from patents. Krystal Biotech's grant share as of January 2024 was 25%. Grant share is based on the ratio of number of grants to total number of patents.

Pharmaceutical composition for skin disorders with polynucleotides

Source: United States Patent and Trademark Office (USPTO). Credit: Krystal Biotech Inc

A pharmaceutical composition for providing relief for skin disorders and diseases is described in a filed patent (Publication Number: US20230414686A1). The composition includes a virus with a vector containing transgenes encoding specific polypeptides such as Collagen alpha-1 (VII) chain, Lysyl hydroxylase 3, and Keratin type I cytoskeletal 17, along with a pharmaceutically acceptable carrier. The vector is a recombinant herpes simplex virus genome, with the ability to enhance various cellular functions related to skin health.

The method outlined in the patent involves administering the pharmaceutical composition to a subject to provide prophylactic, palliative, or therapeutic relief for skin wounds, disorders, or diseases. The composition, which includes the recombinant herpes simplex virus genome and specific transgenes, aims to increase the levels of key polypeptides in the subject's cells. The application of the composition can be topical or transdermal, making it suitable for various skin conditions like epidermolysis bullosa, psoriasis, eczema, and more. The patent details the specific genes targeted within the herpes simplex virus genome and the potential benefits of expressing the encoded polypeptides in the subject's cells for improving skin health.

To know more about GlobalData’s detailed insights on Krystal Biotech, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies